La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Avanos Medical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Avanos Medical..

Avanos Medical (NYSE:AVNS) Azioni, Catena delle Opzioni

Avanos Medical

Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.

Avanos Medical Inc

Earnings

News

Telefonica Q3 Sales $11.02B Down From $11.23B YoY

HYMTF

Reported Earlier, BlackBerry QNX Chosen By Hyundai Mobis For Advanced Digital Cockpit Platform, Enabling Safer, Smarter Driving

Company Intends to Use Any Proceeds to Further Accelerate the Expansion of Its Next Generation Spaceflight Fleet, Including the Production of an Additional Mothership

SPCE

Reported Earlier, Virgin Galactic Launches $300M At-The-Market Equity Program To Fund Fleet Expansion

The Selling Stockholders will receive all of the net proceeds from the Offering. The Company will not sell any shares of its common stock in the Offering and will not receive any of the proceeds from the sale of shares of the Company's common stock in the Offering. &nbsp;

ALKT

Reported Earlier, Alkami Technology Prices 7.5M Share Secondary Offering, Backed By Key Investors

Taiwan&#8217;s China Airlines is reportedly on the verge of splitting a substantial order for long-haul passenger jets between Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) and Airbus SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/EADSY#OTC">EADSY</a>). This decision aligns with the recent U.S. presidential election outcome, where Republican Donald Trump reclaimed the presidency.
What Happened: The airline is evaluating Boeing&#8217;s 777X and Airbus&#8217;s A350-1000 models to replace its existing fleet of 10 Boeing 777-300ERs. The order could encompass up to 20 passenger jets, potentially divided equally between the two manufacturers. The decision on freighters remains uncertain, influenced by the political climate post-U.S. elections, Reuters reported on Thursday.
The estimated value of this passenger jet order is approximately $4 billion, considering standard industry discounts, as reported by aviation consultancy Cirium Ascend. The airline&#8217;s board is yet to finalize the decision, with no confirmation on the exact number and types of planes involved.
See Also: <a href="https://www.benzinga.com/news/24/11/41704893/steve-ballmer-is-betting-40m-on-facts-as-heated-trump-harris-battle-reaches-peak-crescendo-how-ex-mi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Steve Ballmer Is Betting $40M On Facts As Heated Trump-Harris Battle Reaches Peak Crescendo — How Ex-Microsoft CEO Aims To Rescue American Democracy With Data</a>
China Airlines, primarily owned by the Taiwan government, previously ordered 16 Boeing 787-9s in 2022. Despite past concerns, Taiwan&#8217;s government remains optimistic about maintaining robust relations with the U.S. under Trump&#8217;s leadership. The airline&#8217;s chairman, Hsieh Shih-chien, stressed that fleet decisions are made independently of political influence.
Why It Matters: The aerospace industry has been under scrutiny, with companies like Boeing and Airbus facing questions about their high valuations. Defense and aerospace stocks have shown a <a href="https://www.benzinga.com/markets/equities/24/10/41342896/aerospace-stocks-face-tough-questions-can-boeing-ge-airbus-justify-sky-high-valuations">remarkable 22% return</a> year-to-date, driven by geopolitical tensions.
Additionally, <a href="https://www.benzinga.com/markets/equities/24/11/41736062/boeing-workers-end-seven-week-strike-by-accepting-new-contract-with-major-pay-increases">Boeing&#8217;s recent labor agreement</a> ended a seven-week strike, securing significant pay increases for workers, which could impact production costs. Meanwhile, <a href="https://www.benzinga.com/news/24/10/41273419/airbus-announces-85-new-orders-pointers-show-air-india-is-purchaser-report">Airbus&#8217;s recent orders</a> highlight its strong market position, with 85 new orders reported in September.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41765113/elon-musk-tells-tucker-carlson-that-the-pressure-he-faced-for-shutting-down-x-pales-in-comparison-wi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Tells Tucker Carlson That The Pressure He Faced For Shutting Down X &#8216;Pales In Comparison&#8217; With What Trump Went Through</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

General

European Aeronautic Defence And Space Unsponsored

EADSY

Boeing, Airbus Might Secure A $4B Jet Order From Taiwan's China Airlines As Trump Secures Second Term: Report

ChatGPT-parent OpenAI, under the leadership of Sam Altman, has taken over the domain chat.com, which was previously under the ownership of HubSpot&#8216;s founder and CTO, Dharmesh Shah.
What Happened: On Wednesday, Altman posted a cryptic post on X, formerly Twitter, using the words, &#8220;chat.com,&#8221; only. The URL now redirects to ChatGPT.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://t.co/n494J9IuEN">https://t.co/n494J9IuEN</a>
&mdash; Sam Altman (@sama) <a href="https://twitter.com/sama/status/1854238332534108188?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Following Altman&#8217;s post, Shah also took to X and confirmed the purchase, indicating that he might have received OpenAI shares in exchange for the domain.
See Also: <a href="https://www.benzinga.com/news/large-cap/24/11/41703422/google-delivers-new-ai-features-to-maps-google-earth-waze-apps?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Google Delivers New AI Features To Maps, Google Earth, Waze Apps</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">BREAKING NEWS: Secret acquirer of $15+ million domain chat .com revealed and it&#39;s exactly who you&#39;d think. For those of you that have been following me for a while, you may recall that I announced earlier this year that I had acquired the domain chat .com for an &quot;8 figure sum&quot;… <a href="https://t.co/nv1IyddP5z">https://t.co/nv1IyddP5z</a>
&mdash; dharmesh (@dharmesh) <a href="https://twitter.com/dharmesh/status/1854307883304792294?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Shah had initially bought the domain for $15.5 million in early 2023 but sold it a few months later for an undisclosed amount, which he confirmed was higher than the purchase price.
Shah&#8217;s initial purchase of chat.com was driven by his belief in the potential of Chat-based UX, facilitated by Generative AI.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: OpenAI&#8217;s acquisition of chat.com follows its recent transition from a nonprofit to a for-profit model, a move that sparked a <a href="https://www.benzinga.com/startups/24/10/41556636/microsoft-and-openai-clash-over-14-billion-as-the-ai-leader-converts-to-a-for-profit-business-disrup">financial and governance tug-of-war</a> with Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
The ChatGPT parent has been on a financial upswing, with its <a href="https://www.benzinga.com/news/24/10/41149788/openai-valuation-soars-to-157b-in-latest-funding-round">valuation soaring to $157 billion</a> in its latest funding round. Previously, it was reported that the AI startup intends to <a href="https://www.benzinga.com/news/24/09/41078513/openai-plans-to-more-than-double-chatgpt-price-over-next-5-years-report">more than double the price</a> of its flagship product, ChatGPT, over the next five years.
Last month, OpenAI rolled out ChatGPT Search, a feature that allows the <a href="https://www.benzinga.com/news/24/10/41663190/openai-rolls-out-chatgpt-search-google-shares-slide">AI to crawl the web</a> for up-to-date news, sports scores, stock quotes, and more.
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41767401/trump-vs-harris-apple-transforms-dynamic-island-to-bring-election-results-at-your-fingertips-on-ipho?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Vs. Harris: Apple Transforms Dynamic Island To Bring Election Results At Your Fingertips On iPhone</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

Tech

MSFT

OpenAI Acquires Dharmesh Shah's $15.5M Domain Chat.com: What's Behind The Move?

Uber's rival ride-hailing platform, Lyft Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) said on Wednesday that it has partnered with Intel Corp.-owned (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) Mobileye, and May Mobility to provide <a href="https://www.benzinga.com/topic/autonomous-vehicles">autonomous vehicle</a> rides to its customers.
What Happened: As part of Lyft&#8217;s partnership with Intel-owned Mobileye, the company will make its scaled rideshare platform available to all vehicles with Mobileye's self-driving technology.
&#8220;The objective is for future AV operators who want to deploy and manage large-scale fleets in various metropolitan areas in North America to purchase Mobileye Drive equipped, "Lyft-ready" vehicles from vehicle builders, access Lyft's rider demand and optimize utilization and profitability of their fleets,&#8221; Mobileye said about the partnership.
The companies, however, did not reveal when the first vehicles with Mobileye&#8217;s self-driving technology will show on the Lyft app.
May Mobility, meanwhile, will directly deploy autonomous vehicles to the Lyft platform in Atlanta starting in 2025, Lyft said. Lyft customers in Atlanta can be matched with a fleet of autonomous Toyota Sienna minivans equipped with May Mobility's autonomous technology as part of the partnership. The company, however, did not specify the number of vehicles that will be deployed. 
"Lyft's aim is to connect AVs, drivers, riders, and partners to create new opportunities for all. Our rideshare network will continue to evolve as millions of people will have the opportunity to earn billions of dollars whether they choose to drive, put their AVs into service, or both," David Risher, CEO of Lyft, said. 
Why It Matters: Lyft&#8217;s AV comes on the heels of Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) announcement that it expects to start an autonomous ride-hail service in Texas and California starting next year, <a href="https://www.benzinga.com/news/24/10/41484511/palo-alto-may-open-streets-to-tesla-robotaxis-but-california-regulators-will-decide-fate" target="_blank" rel="noreferrer noopener">subject to regulatory approval</a>.
However, the vehicles might not all operate as driverless robotaxis initially as some states demand a safety driver until the company touches certain milestones in terms of miles and hours driven, the company then said.
However, company CEO Elon Musk expressed confidence that the company will be <a href="https://www.benzinga.com/top-stories/24/10/41279865/elon-musk-may-unveil-teslas-robotaxi-but-consumers-respond-with-ehhh-new-study-reveals-skepticism-ne" target="_blank" rel="noreferrer noopener">operating driverless paid rides sometime next year.</a>
Tesla also unveiled a no-pedal, no-steering wheel dedicated robotaxi product last month called the Cybercab. Cybercab, Musk then said, will enter production ‘before 2027' and will be priced below $30,000. Until then, the ride-hail fleet will be composed of the company's Model 3 and Model Y.
Uber, meanwhile, has a partnership with Alphabet Inc&#8217;s Waymo since 2023. Earlier this year, Uber said that <a href="https://www.benzinga.com/news/24/10/41665245/alphabets-self-driving-subsidiary-waymo-hits-45-billion-valuation-surpassing-ford-other-major-brands">Waymo and Uber </a>would bring the latter's fully autonomous, all-electric Jaguar I-PACE vehicles to Austin and Atlanta starting in early 2025 on the Uber app.
Price Action: Lyft shares closed up 4.4% at $14.4 on Wednesday, and surged over 20% in after-hours trading. The stock is up 4.4% year-to-date, according to data from<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41767169/spacex-completes-400th-successful-falcon-launch-to-date-but-will-miss-target-of-144-launches-in-2024" target="_blank" rel="noreferrer noopener">SpaceX Completes 400th Successful Falcon Launch To Date, But Will Miss Target Of 144 Launches In 2024, Says Company Exec</a></li>
</ul>
Photo courtesy: Shutterstock

INTC

LYFT

TSLA

Lyft Teams Up With Intel's Mobileye, May Mobility For Robotaxi Services As Tesla Gears Up To Enter Autonomous Riding Hailing Market

PACB

Reported Earlier, PacBio's Vega System Expands Accessibility To HiFi Sequencing, Transforming Benchtop Research

Bill Gates, Microsoft co-founder and longtime artificial intelligence advocate continues to champion AI while acknowledging its unprecedented rapid <a href="https://www.benzinga.com/general/education/24/10/41416721/bill-gates-had-a-very-bad-habit-that-could-have-derailed-his-career">advancement and potential risks</a>.
What Happened: The tech pioneer&#8217;s journey with AI spans nearly a decade. In 2017, at Columbia University, Gates identified artificial intelligence as his chosen field if starting a career today, citing its &#8220;profound&#8221; potential, <a href="https://www.cnbc.com/2024/11/06/bill-gates-predicted-ais-lucrative-potential-nearly-a-decade-ago.html">reported</a> CNBC Make It.
In April, in an episode of his &#8220;Unconfuse Me&#8221; podcast featuring OpenAI CEO Sam Altman, Gates admitted his initial skepticism about AI&#8217;s <a href="https://www.benzinga.com/general/24/04/38159789/bill-gates-worries-ai-will-take-his-job-says-machine-could-say-bill-go-play-pickleball-ive-got-malar">capabilities was misplaced</a>. &#8220;I was very skeptical. I didn&#8217;t expect ChatGPT to get so good,&#8221; Gates said.
Gates particularly noted AI&#8217;s surprising impact on white-collar work, contrary to earlier expectations. During Wednesday&#8217;s &#8220;Possible&#8221; podcast with Reid Hoffman and Aria Finger, he projected that AI robots would expand into construction sites and <a href="https://www.benzinga.com/news/24/11/41736493/microsoft-co-founder-bill-gates-says-everyone-in-future-will-have-a-utilitarian-ai-agent-that-will-h">hotels within ten years</a>.
See Also: <a href="https://www.benzinga.com/news/24/11/41796344/tim-cook-mark-zuckerberg-and-jeff-bezos-congratulate-trump-whats-next-for-the-tech-giants">Tim Cook, Mark Zuckerberg, And Jeff Bezos Congratulate Trump: What&#8217;s Next For The Tech Giants?</a>
Why It Matters: Despite his enthusiasm, Gates expressed concerns <a href="https://www.benzinga.com/general/24/04/38159789/bill-gates-worries-ai-will-take-his-job-says-machine-could-say-bill-go-play-pickleball-ive-got-malar">about AI&#8217;s downsides</a>, including job displacement. &#8220;When the machine says to me, &#8216;Bill, go play pickleball, I&#8217;ve got malaria eradication. You&#8217;re just a slow thinker,&#8217; then it is a philosophically confusing thing,&#8221; he said.
The Microsoft co-founder remains bullish on AI&#8217;s business potential, though he notes increased competition in the sector. &#8220;Today, somebody could raise billions of dollars for a new AI company [that&#8217;s just] a few sketch ideas,&#8221; Gates told CNBC, emphasizing that success now requires &#8220;some unique view of how you design AI systems.&#8221;
Looking ahead, Gates envisions AI transforming programming through natural language interfaces, making coding accessible to everyone. However, he joins other tech leaders in advocating for careful oversight of AI development, particularly regarding election integrity and geopolitical implications.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41785553/alibabas-ai-strategy-massive-ad-spend-to-dominate-crowded-market">Alibaba&#8217;s AI Strategy: Massive Ad Spend to Dominate Crowded Market</a></li>
</ul>
Image Via Flickr 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Bill Gates: AI Will Build Houses, Run Hotels By 2034 — Microsoft Co-Founder Once A Skeptic Now Sees Both Promise And Peril

Rafael Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) reported quarterly losses of $(0.19) per share. This is a 416.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $165.00 thousand in sales this quarter. This is a 142.65 percent increase over sales of $68.00 thousand the same period last year.

Rafael Holdings Q4 EPS $(0.19) Down From $0.06 YoY, Sales $165.00K Up From $68.00K YoY

2025 Early Outlook
<ul>
<li>Providing full-year 2025 Adjusted EBITDA early outlook range of $675 to $725 million</li>
</ul>

Guidance

Kodiak Gas Services Provides 2025 Early Outlook, Sees Adjusted EBITDA Of $675M-$725M

Full-Year 2024 Guidance
Kodiak is providing revised guidance for the full year 2024. The full-year 2024 guidance below incorporates three quarters of the financial impact of the CSI Acquisition that closed on April 1, 2024. Amounts below are in thousands except percentages.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="7" rowspan="1">Full-Year 2024 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">Low</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (1)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">600,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">610,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Discretionary Cash Flow (1)(2)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">365,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">385,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Segment Information</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Contract Services revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">1,020,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">1,040,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Contract Services Adjusted Gross Margin Percentage (1)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">64</td>
<td colspan="1" rowspan="1">%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">66</td>
<td colspan="1" rowspan="1">%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other Services revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">125,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">135,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other Services Adjusted Gross Margin Percentage (1)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">14</td>
<td colspan="1" rowspan="1">%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">17</td>
<td colspan="1" rowspan="1">%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital Expenditures</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Growth capital expenditures (3)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">210,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">230,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Maintenance capital expenditures</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">60,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">70,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Kodiak Gas Services Revised 2024 Guidance: Now Expects Adjusted EBITDA Of $600M-$610M (Prior $590M-$610M), Sees Discretionary Cash Flow Of $365M-$385M

Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.37 by 86.49 percent. The company reported quarterly sales of $324.647 million which beat the analyst consensus estimate of $316.749 million by 2.49 percent. This is a 40.55 percent increase over sales of $230.983 million the same period last year.

Earnings Beats

Earnings Misses

Kodiak Gas Services Q3 2024 Adj. EPS $0.05 Misses $0.37 Estimate, Sales $324.647M Beat $316.749M Estimate

A mysterious trader, dubbed the &#8220;Trump whale,&#8221; is<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41772749/donald-trumps-re-election-nets-french-trump-whale-almost-50-million"> set to gain nearly $50 million</a> after making bold bets related to the U.S. presidential election. The trader, identified as &#8220;Théo,&#8221; accurately forecasted Donald Trump&#8216;s victory, including his win in the popular vote, despite widespread skepticism from analysts.
Théo placed his bets on Polymarket, a crypto-based betting platform, using four anonymous accounts. He communicated with a Wall Street Journal reporter, explaining that his strategy stemmed from a distrust of polling data. Théo, a wealthy Frenchman with a banking background, used his mathematical expertise to scrutinize U.S. polls, concluding they exaggerated support for Vice President Kamala Harris, The Wall Street Journal <a href="https://www.wsj.com/finance/how-the-trump-whale-correctly-called-the-election-cb7eef1d">reported</a> on Wednesday.
See Also: <a href="https://www.benzinga.com/news/24/11/41793530/bernie-sanders-says-american-people-are-angry-and-want-change-and-theyre-right-democrats-have-abando?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bernie Sanders Says &#8216;American People Are Angry And Want Change&#8217; And &#8216;They&#8217;re Right&#8217; — Democrats Have Abandoned The Working Classes</a>
Théo&#8217;s wagers, exceeding $30 million, were essentially a challenge to conventional polling methods. As election results began to unfold, Théo remained confident, especially after Trump&#8217;s strong showing in Florida. The Wall Street Journal confirmed Théo&#8217;s identity as the trader behind four anonymous Polymarket accounts, with Polymarket verifying his French nationality and trading experience.
The &#8220;Fredi tracker&#8221; monitoring the accounts linked to Théo shows his total gains reaching nearly $49.5 million, with his current portfolio valued at $100.7 million on Polymarket. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41733346/obamas-former-campaign-manager-alarmed-by-early-voting-numbers-as-harris-trump-fight-close-battle-re?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Obama&#8217;s Former Campaign Manager Alarmed By Early Voting Numbers As Harris-Trump Fight Close Battle: &#8216;Republicans Didn&#8217;t Do What They Did Last Time&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Flickr

Markets

How Mystery 'Trump Whale' Reaps $50M Profit By Betting Against Polling Data

NBA star Scottie Pippen's "dream encounter" with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) creator Satoshi Nakamoto failed to hit the bull&#8217;s eye, as the leading cryptocurrency gained but didn't gain enough on election day.
What happened: Widely regarded as one of the greatest players in NBA history,&nbsp; Pippen is a known celebrity advocate of Bitcoin and actively uses his social media presence to promote the cryptocurrency.&nbsp;
Earlier in September, he described one of his dreams that piqued the interest of the Bitcoin community.
Pippen said that none other than the pseudonymous Satoshi appeared in his dreams and predicted that the dominant cryptocurrency would hit $84,650 on Nov. 5, the day of the elections.
However, he added that this wasn't any financial advice.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f440; <a href="https://t.co/xiP2MV0opL">https://t.co/xiP2MV0opL</a>
&mdash; Scottie Pippen (@ScottiePippen) <a href="https://twitter.com/ScottiePippen/status/1854296230245118169?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41796743/ethereum-whales-wake-up-from-slumber-to-cash-out-90m-amid-rally-but-indicators-show-sentim">Ethereum Whales Wake Up From Slumber To Cash Out $90M Amid Rally, But Indicators Show Sentiment Can Flip</a>
As it turned out, Bitcoin soared on Donald Trump's victory but missed &#8220;Satoshi's projection&#8221;. The apex cryptocurrency's rally was halted at a high of $76,460.
Details about Pippen&#8217;s Bitcoin or cryptocurrency holdings have been sketchy, and the iconic athlete did not immediately respond to Benzinga's request for more information.
Why It Matters: Price predictions for Bitcoin were in full swing leading up to the election, and they are certain to continue as market expectations have only grown.
A potential Trump win being the bull case, global investment bank Standard Chartered had earlier <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40835368/bitcoin-will-hit-125k-if-donald-trump-wins-75k-in-case-of-a-kamala-harris-victory-standard">projected </a>Bitcoin to shoot to $125,000. Brokerage firm Bernstein projected the leading cryptocurrency <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40778409/donald-trump-winning-the-election-could-propel-bitcoin-to-90k-but-a-kamala-harris-win-coul">to hit $80,000 to $90,000</a> by the end of Q4 should Trump emerge victorious.
Price Action: At the time of writing, Bitcoin was exchanging hands at $74,605.01 down 0.14% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Photo courtesy: Unsplash
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41795154/ripple-ceo-brad-garlinghouse-proposes-crypto-blueprint-for-trumps-first-100-days-fire-gens">Ripple CEO Brad Garlinghouse Proposes Crypto Blueprint For Trump&#8217;s First 100 Days: &#8216;Fire Gensler. Day 1, No Delays&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Sports

$BTC

NBA legend Scottie Pippen's Prophetic 'Satoshi Nakamoto Dream' Misses Bitcoin Numbers On Election Day

Fortuna Silver Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 77.78 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $274.900 million which beat the analyst consensus estimate of $265.956 million by 3.36 percent. This is a 13.08 percent increase over sales of $243.100 million the same period last year.

Fortuna Silver Mines Q3 2024 Adj. EPS $0.16 Beats $0.12 Estimate, Sales $274.900M Beat $265.956M Estimate

Equinox Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EQX#AMEX">EQX</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.12 by 25 percent. This is unchanged from the same period last year. The company reported quarterly sales of $428.400 million which missed the analyst consensus estimate of $437.836 million by 2.16 percent. This is a 50.47 percent increase over sales of $284.700 million the same period last year.

Equinox Gold Q3 2024 Adj. EPS $0.09 Misses $0.12 Estimate, Sales $428.400M Miss $437.836M Estimate

Outlook
We are pleased to reaffirm our guidance midpoint for 2024, reflecting the continued strength of our financial performance, the positive underlying momentum in our business as well as the positive contribution from portfolio activity.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">2024 Guidance</td>
<td colspan="2" rowspan="1">Updated Guidance Range (i)</td>
<td colspan="2" rowspan="1">Previous Guidance Range (ii)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(in $ billions, except per share data)</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net income</td>
<td colspan="1" rowspan="1">3.78</td>
<td colspan="1" rowspan="1">3.85</td>
<td colspan="1" rowspan="1">3.70</td>
<td colspan="1" rowspan="1">3.85</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA&#x2A;</td>
<td colspan="1" rowspan="1">6.87</td>
<td colspan="1" rowspan="1">6.97</td>
<td colspan="1" rowspan="1">6.82</td>
<td colspan="1" rowspan="1">7.02</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EPS</td>
<td colspan="1" rowspan="1">$5.45</td>
<td colspan="1" rowspan="1">$5.55</td>
<td colspan="1" rowspan="1">$5.40</td>
<td colspan="1" rowspan="1">$5.60</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditure</td>
<td colspan="1" rowspan="1">2.4</td>
<td colspan="1" rowspan="1">2.6</td>
<td colspan="1" rowspan="1">2.2</td>
<td colspan="1" rowspan="1">2.4</td>
</tr>
</tbody>
</table>
</figure>

CRH Expects 2024 EPS Of $5.45-$5.55 (Prior $5.40-$5.60) Vs $5.52 Est., And Adj EBITDA Of $6.87B-$6.97B (Prior $6.82B-$7.02B)

CRH Q3 2024 GAAP EPS $1.97 Miss $2.09 Est, Sales $10.515B Miss $10.56B Est

Macro Economic Events

Econ #s

Economics

Germany Trade Balance For September 17.0B Vs. 20.8B Est.; 22.5B Prior

Stifel Nicolaus analyst Rick Wise maintained a Hold rating on Avanos Medical (AVNS – Research Report) yesterday and set a price target of $24.00. T...

Stifel Nicolaus Remains a Hold on Avanos Medical (AVNS)

The medical industry is on the fence of explosive growth, fueled by technological advancements. In this evolving landscape, investors could consider investing in promising medical device stocks like Hologic, Inc. (HOLX), Avanos Medical (AVNS), and Embecta Corp. (EMBC) with solid growth prospects. Learn more… Thanks to cutting-edge technology, medical stocks are effectively reshaping the healthcare sector. The industry is experiencing significant growth, driven by increasing demand for advanced healthcare solutions, particularly in diagnostics, surgeries, and patient monitoring.
Given this backdrop, investors looking for growth opportunities could take a look at these three fundamentally robust medical device stocks: Hologic, Inc. (<a href="https://stocknews.com/stock/HOLX/">HOLX</a>), Avanos Medical, Inc. (<a href="https://stocknews.com/stock/AVNS/">AVNS</a>), and Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>). These companies are shaping healthcare delivery's future and benefitting from technological advancements.
The medical devices industry is poised for steady growth as its market size is anticipated to reach <a href="https://www.mordorintelligence.com/industry-reports/global-medical-device-technologies-market-industry?network=g&amp;source_campaign=&amp;utm_source=google&amp;utm_medium=cpc&amp;matchtype=b&amp;device=c&amp;gad_source=1&amp;gclid=Cj0KCQjwpP63BhDYARIsAOQkATb9SdZ7QZMMYB0trPXq_zr3V73FHtcX5g9Z7xWnrv4R67MwdKzHOV0aApKdEALw_wcB">$893.07 billion by 2029</a>, exhibiting a CAGR of 7%. Moreover, by 2030, the global annual medical device sales are forecasted to <a href="https://kpmg.com/us/en/articles/2023/medical-devices-2030.html#:~:text=The%20medical%20device%20industry%20is,US%24800%20billion%20by%202030%20.">hit $800 billion</a>.
Moreover, innovations like AI-powered diagnostic tools, wearable health devices, and robotic surgery systems are revolutionizing patient care. The FDA has already authorized <a href="https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices#:~:text=the%20FDA%20has%20authorized%20950%20AI/ML%2Denabled%20medical%20devices.">950 AI/ML-enabled medical devices</a>, which promise faster diagnoses, more precise treatments, and improved patient outcomes.
Considering these favorable trends, let's look at the fundamentals of the above-mentioned <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> picks in detail:
Stock #3: Hologic, Inc. (<a href="https://stocknews.com/stock/HOLX/">HOLX</a>)
HOLX is a medical technology company focused on improving women's health and well-being through early detection and treatment. It is a developer, manufacturer, and supplier of worldwide diagnostics, medical imaging systems, and surgical products. The company operates through four segments: Diagnostics; Breast Health; GYN Surgical; and Skeletal Health.
On July 25, HOLX acquired Endomagnetics Ltd., a privately held UK-based developer of breast cancer surgery technologies, for $310 million. This acquisition enhances access to Endomag's innovative technologies and diversifies HOLX's expanding interventional breast health portfolio.
In the fiscal third quarter that ended on June 29, 2024, HOLX's total revenue increased 2.7% year-over-year to $1.01 billion with a non-GAAP gross margin of 61.1% (up 30 bps year-over-year). The company reported income from operations of $244 million, indicating a significant growth from the prior year quarter.
In addition, its adjusted EBITDA increased 8.5% year-over-year to $338.50 million. HOLX's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> came in at $250.70 million, up 8.4% year-over-year, while its non-GAAP EPS grew 14% from the year-ago value to $1.06.
For the fourth quarter of the fiscal year 2024, the company's revenue is projected to be between $970 million and $985 million, with non-GAAP EPS anticipated to fall between $0.97 and $1.04.
The consensus revenue estimate of $977.49 million for the fiscal fourth quarter (ended September 2024) represents a 3.4% increase year-over-year. The consensus EPS estimate of $1.01 for the same quarter indicates a 13.9% improvement year-over-year. The company has an impressive surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Over the past three and five years, HOLX's total assets grew at CAGRs of 1.2% and 6.4%, respectively. Also, the company's normalized net income and operation income (EBIT) have increased at a CAGR of 16.8% and 10.9%, respectively, over the past five years.
Shares of HOLX have gained 14.3% over the past year to close the last trading session at $79.22.
HOLX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
HOLX has a B grade for Growth and Quality. It is ranked #14 out of 134 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. <a href="https://stocknews.com/stock/HOLX/">Click here</a> to see the additional ratings for HOLX (Value, Momentum, Stability, and Sentiment).
 Stock #2: Avanos Medical, Inc. (<a href="https://stocknews.com/stock/AVNS/">AVNS</a>)
AVNS is a medical device company that focuses on delivering medical device solutions. The company conducts its business in one segment, which provides its medical device products to healthcare providers and patients globally with manufacturing facilities.
AVNS' net sales for the second quarter (ended June 30, 2024) increased marginally year-over-year to $171.70 million. Its non-GAAP operating profit from continuing operations grew 18.5% from the prior year's quarter to $21.80 million. The company's net income stood at $1.80 million compared to the prior-year quarter's loss of $68.10 million, while its EPS came in at $0.04 versus a loss of $1.46 per share last year.
In addition, AVNS' adjusted EBITDA from continuing operations rose 17% from the year-ago value to $26.80 million. Its free cash flow came in at $21.90 million compared to a year-ago net loss of $6.6 million.
As per the fiscal year 2024 outlook, AVNS forecasts revenue from continuing operations to range between $685 million and $705 million. The company also expects adjusted EPS from continuing operations between $1.30 and $1.45 and adjusted gross margins from continuing operations to fall in the range of 59.5%-60.5%.
Street expects AVNS' revenue for the fiscal third quarter (ended September 2024) to increase 2.4% year-over-year to $175.33 million. Its EPS for the same period is expected to register a 17.8% growth from the prior year, settling at $0.35. In addition, it surpassed the consensus revenue in each of the trailing four quarters, which is promising.
Moreover, AVNS' EBITDA and net income have grown at CAGRs of 32.7% and 47.5%, respectively, over the past three years. In addition, its EPS increased at 60.6% CAGR over the same time frame.
Over the past three months, the stock has surged 18.5%, closing the last trading session at $23.02.
It's no surprise that AVNS has an overall rating of B, equating to a Buy in our POWR Ratings system. It has an A grade for Growth and a B for Value. Out of 134 stocks in the same industry, AVNS is ranked #12.
Beyond what is stated above, we've also rated AVNS for Momentum, Stability, Sentiment, and Quality. Get all AVNS ratings <a href="https://stocknews.com/stock/AVNS/">here</a>.
Stock #1: Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>)
EMBC is a global diabetes care company focusing on providing various solutions to enhance the health and well-being of people with diabetes. It has a portfolio of products that include pen needles, syringes, safety injection devices, and digital applications to assist people with managing patient's diabetes. 
On September 3, EMBC received clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system, required for adults who require insulin, both type 1 (T1D) and type 2 (T2D) diabetes, to be managed. This clearance aligns with the company's vision and focuses on developing a patch pump, addressing obstacles to adopting pump therapy for people who use insulin daily to manage their diabetes. 
For the third quarter of 2024, which ended on June 30, EMBC's revenue stood at $272.50 million. Its adjusted operating income grew 4.4% from the year-ago value to $83.30 million. Its adjusted net income for the quarter amounted to $43 million or $0.74 per share, representing an increase of 8% and 7.2%, respectively, from the same period last year. Also, the company reported an adjusted EBITDA of $99.20 million, indicating a 15.5% growth from the prior year's quarter.
The company has updated its fiscal year 2024 financial guidance, increasing its adjusted gross margin projection to a range of 65.25% to 65.50%, up from the previous estimate of 64.5% to 65%. Additionally, it adjusted its non-GAAP EPS guidance to a new range of $2.30 to $2.35, slightly higher than the prior forecast of $2.20 to $2.30.
Moreover, its adjusted EBITDA margin is expected to range between 31.25%-31.50%, an increase from the previous estimate of 31%-31.5%. Meanwhile, EMBC projects its revenue to fall in the range of $1.11 billion to $1.12 billion.
Analysts expect EMBC's revenue and EPS for the current year (ending September 2024) to be $1.11 billion and $2.39, respectively. For the fiscal year 2025, its revenue is expected to grow marginally from the prior year to $1.12 billion, and its EPS is projected to come in at $2.27.
Over the past year, EMBC's net income has increased at a CAGR of 47.7%, while its EPS grew at 45.3% CAGR.
EMBC shares have surged 10.1% over the past three months to close the last trading session at $13.29.
EMBC's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Value and Quality and a B for Growth. Within the Medical - Devices &amp; Equipment industry, it is ranked #3. <a href="https://stocknews.com/stock/EMBC/">Click here</a> to see EMBC's ratings for Momentum, Stability, and Sentiment.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
HOLX shares were trading at $79.88 per share on Friday morning, up $0.66 (+0.83%). Year-to-date, HOLX has gained 11.80%, versus a 20.77% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/holx-avns-embc-3-medical-device-stocks-with-strong-growth-prospects/>3 Medical Device Stocks With Strong Growth Prospects</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Medical Device Stocks With Strong Growth Prospects

Avanos Medical Non-GAAP EPS of $0.36 beats by $0.01, revenue of $170.4M misses by $4.93M

Avanos Medical Inc. (AVNS) Q3 2024 Earnings Call Transcript

Stifel lowered the firm's price target on Avanos (AVNS) to $20 from $24 and keeps a Hold rating on the shares after the company announced the retir...

Avanos price target lowered to $20 from $24 at Stifel

Avanos Medical, Inc. ( ($AVNS) ) has realeased its Q3 earnings. Here is a breakdown of the information Avanos Medical, Inc. presented to its invest...

Avanos Medical Reports Q3 Results and CEO Retirement

JMP Securities analyst Daniel Stauder has reiterated their neutral stance on AVNS stock, giving a Hold rating yesterday. Daniel Stauder's rating is...

Avanos Medical: Navigating Leadership Changes Amidst Sales Challenges and Strategic Adjustments

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS – Research Report), Avanos Medical (AVNS...

Comments

Avanos Medical

Avanos Medical (AVNS) Opzioni

Avanos Medical (NYSE:AVNS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO